Skip to main content
Premium Trial:

Request an Annual Quote

GPC Biotech and Boehringer Ingelheim Collaborate on Drug Target Project

NEW YORK, Jan 9 – GPC Biotech has signed on to a proteomics and genomics deal with Boehringer Ingelheim pharmaceuticals, in which GPC will identify targets and pathways associated with human papillomavirus, GPC announced Tuesday.

In this project, GPC Biotech is using OliCode molecular cloning technology, PathCode yeast two-hybrid protein-protein interaction identification technology, and its bioinformatics applications.

Based on these targets, Boehringer Ingelheim hopes to develop new treatments and preventative therapies for HPV-related illnesses.

Boehringer Ingelheim is paying GPC Biotech license fees, milestone payments for clinical development, and royalties on sales of any products it develops using GPC Biotech’s targets.

Boehringer Ingelheim will also provide research funding for research. GPC estimated that total payments from Boehringer Ingelheim could add up to $30 million.

This deal follows an earlier collaboration, in which GPC Biotech defined gene expression profiles for Boehringer Ingleheim using its ExpressCode technology and provided information about target function.

GPC has also formed similar partnerships with Aventis, Bayer, Du Pont, Altana, Cell Genesys, Maxim Pharmaceuticals, Evotec Biosystems, Morphosys, and Karo Bio.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.